Navigating IBD During the Coronavirus Pandemic
Read More
Switching Between Biologics in Inflammatory Bowel Disease
Inflammatory Bowel Disease: Initiating Therapy
Inflammatory Bowel Disease: Limitations in Treatment
IBD Treatment: Translating Data Into Clinical Practice
Vedolizumab and Ustekinumab for IBD
Managing IBD With Anti-TNF Therapy
Inflammatory Bowel Disease: Treatment Advances
Telemedicine to Monitor Patients With IBD During COVID-19
Optimizing Therapy for IBD During COVID-19
Anticytokine Therapy for IBD and COVID-19
COVID-19 and Inflammatory Bowel Disease
Concerns Surrounding Increasing Rates of Inflammatory Bowel Disease
The Future of T2DM Management
Advice for Cardiologists Managing T2DM
The Collaborative Management of T2DM
Ongoing Trials and Lifestyle Changes
Ensuring an Accurate Diagnosis of T2DM
Available Treatments for Type 2 Diabetes
T2DM Management: Endocrinologist or Local Physician?
Pathophysiology of T2DM and Cardiovascular Disease
Management of Lipid Disorders: Multidisciplinary Teams
Safety of PCSK9 Inhibitors in Clinical Practice
Using Apheresis in Lowering Lp(a)
Approaching Statin Intolerance in Patients With CVD Risk
Emerging Agents for the Management of CVD
Role of OTC Medications in Managing CVD Risk
Approaching Management of Cardiovascular Events With Statins
Lifestyle Modifications for Patients at Risk for CVD
Practical Management of Patients at Risk for CVD